Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenstrom's macroglobulinemia

Next Previous
Trial Profile

HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenstrom's macroglobulinemia

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HOVON 124 WM; HOVON 124 WM/ECWM-R2

    • Most Recent Events

    • 10 Apr 2024 This study has been completed in Greece, according to European Clinical Trials Database record.
    • 13 Aug 2021 Primary endpoint has been met. (Primary Endpoint phase II: overall response rate (including CR, VGPR, PR and MR) after 8 cycles of ixazomib citrate, rituximab and dexamethasone, measured at 3 months after start of the last cycle (prior to the start of maintenance)) as per results published in the Journal of Clinical Oncology
    • 13 Aug 2021 Results assessing combination of Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenstrom's Macroglobulinemia published in the Journal of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top